(Q35914787)

English

Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

scientific article published in January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection (English)

1 reference

Europe PubMed Central

11 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jian-Feng Lu

1

1 reference

Europe PubMed Central

11 August 2017

Erik Rasmussen

2

1 reference

Europe PubMed Central

11 August 2017

Beth Y Karlan

3

1 reference

Europe PubMed Central

11 August 2017

Ignace B Vergote

4

1 reference

Europe PubMed Central

11 August 2017

Lynn Navale

5

1 reference

Europe PubMed Central

11 August 2017

Mita Kuchimanchi

6

1 reference

Europe PubMed Central

11 August 2017

Rebeca Melara

7

1 reference

Europe PubMed Central

11 August 2017

Daniel E Stepan

8

1 reference

Europe PubMed Central

11 August 2017

David M Weinreich

9

1 reference

Europe PubMed Central

11 August 2017

Yu-Nien Sun

10

1 reference

Europe PubMed Central

11 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2012

1 reference

Europe PubMed Central

11 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

11 August 2017

69

1 reference

Europe PubMed Central

11 August 2017

1135-1144

1 reference

Europe PubMed Central

11 August 2017

5

1 reference

Europe PubMed Central

11 August 2017

https://scigraph.springernature.com/pub.10.1007/s00280-011-1787-5

0 references

Pharmacometrics 2020.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

PK/PD modelling and simulations: utility in drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Maximizing the potential of bevacizumab in cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Challenges of PK/PD measurements in modern drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

11 July 2018

Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Applying physiological and biochemical concepts to optimize biological drug development.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Recommended changes to oncology clinical trial design: revolution or evolution?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3337406

24 September 2018

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22210018

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II oncology trials: let's be positive

1 reference

https://pubmed.ncbi.nlm.nih.gov/22210018

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What is the right dose? The elusive optimal biologic dose in phase I clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/22210018

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose selection in phase I studies: why we should always go for the top

1 reference

https://pubmed.ncbi.nlm.nih.gov/22210018

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22210018

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/22210018

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-011-1787-5

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35914787&oldid=1866311515"